{"id":53431,"date":"2023-01-30T19:02:03","date_gmt":"2023-01-30T18:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/"},"modified":"2023-01-30T19:02:03","modified_gmt":"2023-01-30T18:02:03","slug":"worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/","title":{"rendered":"Worldwide Cancer Immunotherapy Industry to 2033 &#8211; Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5703354\/cancer-immunotherapy-market-by-product?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=5chbfm&amp;utm_campaign=1814956+-+Worldwide+Cancer+Immunotherapy+Industry+to+2033+-+Featuring+Novartis%2C+Pfizer%2C+AstraZeneca+and+Genentech+Among+Others&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region &#8211; Global Forecast to 2022-2033&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe cancer immunotherapy market size is estimated to be USD 110,125.4 million in 2022 and is expected to witness a CAGR of 7.51% during the forecast period 2023-2033.\n<\/p>\n<p>\n<strong>Companies Mentioned:<\/strong>\n<\/p>\n<ul>\n<li>\nNovartis AG\n<\/li>\n<li>\nLilly\n<\/li>\n<li>\nPfizer Inc\n<\/li>\n<li>\nAstraZeneca\n<\/li>\n<li>\nPfizer Inc\n<\/li>\n<li>\nMerck &amp; Co. Inc\n<\/li>\n<li>\nBristol-Myers Squibb Company\n<\/li>\n<li>\nJohnson &amp; Johnson Services Inc\n<\/li>\n<li>\nF. Hoffmann-La Roche Ltd\n<\/li>\n<li>\nGenentech Inc (Roche)\n<\/li>\n<li>\nImmunocore Ltd.\n<\/li>\n<\/ul>\n<p>\nSurge in oncology incidence around the world and spike in R&amp;D efforts for the creation of novel oncology treatments are factors contributing to the market growth.\n<\/p>\n<p>\nAdditionally, rise in funds for the development of innovative therapies and various strategic measures implemented by top companies is supporting the market growth. However, immunotherapy adverse effects are expected to hinder the growth.\n<\/p>\n<p>\nRise in funds for the development of innovative therapies is expected to propel the market growth during the projected period. For instance, the U.S. National Cancer Institute and Cancer Research UK&#8217;s Cancer Grand Challenges project provided USD 13 million in funding to a team of Stanford scientists in June 2022. The creation of new immunotherapies, research into extrachromosomal DNA, and analysis of early-stage cancers are all recipients of this funding.\n<\/p>\n<p>\nVarious strategic measures implemented by top companies is predicted to fuel the market growth during the forecast period. For instance, in August 2022, Genmab A\/S and BioNTech SE strengthened their strategic partnership for the creation and introduction of novel immune treatments for the management of various cancer types.\n<\/p>\n<p>\nAdditionally, Merck &amp; Co., Inc. announced in March 2022 that the US FDA has approved KEYTRUDA. An anti-PD-1 therapy named KEYTRUDA is used to treat advanced endometrial cancer.\n<\/p>\n<p>\n<strong>Market Segmentation<\/strong>\n<\/p>\n<p>\n<strong>Product (Revenue, USD Million), 2022 &#8211; 2033<\/strong>\n<\/p>\n<ul>\n<li>\nImmunomodulators\n<\/li>\n<li>\nMonoclonal Antibodies\n<\/li>\n<li>\nOncolytic Viral Therapies &amp; Cancer Vaccines\n<\/li>\n<\/ul>\n<p>\n<strong>Distribution Channel (Revenue, USD Million), 2022 &#8211; 2033<\/strong>\n<\/p>\n<ul>\n<li>\nOnline Pharmacy\n<\/li>\n<li>\nHospital Pharmacy\n<\/li>\n<li>\nRetail Pharmacy\n<\/li>\n<\/ul>\n<p>\n<strong>Application (Revenue, USD Million), 2022 &#8211; 2033<\/strong>\n<\/p>\n<ul>\n<li>\nBreast Cancer\n<\/li>\n<li>\nLung Cancer\n<\/li>\n<li>\nColorectal Cancer\n<\/li>\n<li>\nProstate Cancer\n<\/li>\n<li>\nPancreatic Cancer\n<\/li>\n<li>\nMelanoma\n<\/li>\n<li>\nOvarian Cancer\n<\/li>\n<li>\nHead and Neck Cancer\n<\/li>\n<li>\nOthers\n<\/li>\n<\/ul>\n<p>\n<strong>End Use (Revenue, USD Million), 2022 &#8211; 2033<\/strong>\n<\/p>\n<ul>\n<li>\nCancer Research Centres\n<\/li>\n<li>\nHospitals &amp; Clinics\n<\/li>\n<li>\nOthers\n<\/li>\n<\/ul>\n<p>\n<strong>By Region (Revenue, USD Million), 2022 &#8211; 2033<\/strong>\n<\/p>\n<p>\n<strong>North America<\/strong>\n<\/p>\n<ul>\n<li>\nU.S.\n<\/li>\n<li>\nCanada\n<\/li>\n<\/ul>\n<p>\n<strong>Europe<\/strong>\n<\/p>\n<ul>\n<li>\nGermany\n<\/li>\n<li>\nFrance\n<\/li>\n<li>\nUK\n<\/li>\n<li>\nSpain\n<\/li>\n<li>\nItaly\n<\/li>\n<li>\nRest of Europe\n<\/li>\n<\/ul>\n<p>\n<strong>Asia Pacific<\/strong>\n<\/p>\n<ul>\n<li>\nChina\n<\/li>\n<li>\nJapan\n<\/li>\n<li>\nIndia\n<\/li>\n<li>\nAustralia\n<\/li>\n<li>\nSouth Korea\n<\/li>\n<li>\nRest of APAC\n<\/li>\n<\/ul>\n<p>\n<strong>Latin America<\/strong>\n<\/p>\n<ul>\n<li>\nBrazil\n<\/li>\n<li>\nMexico\n<\/li>\n<li>\nArgentina\n<\/li>\n<li>\nRest of LATAM\n<\/li>\n<\/ul>\n<p>\n<strong>Middle East &amp; Africa<\/strong>\n<\/p>\n<ul>\n<li>\nSouth Africa\n<\/li>\n<li>\nGCC\n<\/li>\n<li>\nRest of MEA\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5703354\/cancer-immunotherapy-market-by-product?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=5chbfm&amp;utm_campaign=1814956+-+Worldwide+Cancer+Immunotherapy+Industry+to+2033+-+Featuring+Novartis%2C+Pfizer%2C+AstraZeneca+and+Genentech+Among+Others&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/6ag9at<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x70;&#114;e&#x73;&#x73;&#64;r&#x65;&#115;e&#x61;&#x72;&#99;h&#x61;&#x6e;&#100;&#x6d;&#x61;&#114;k&#x65;&#x74;&#115;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#115;&#64;&#114;es&#x65;&#x61;&#x72;&#x63;&#x68;&#97;&#110;&#100;ma&#x72;&#x6b;&#x65;&#x74;&#x73;&#46;&#99;&#111;m<\/a>\n<\/p>\n<p>\nFor E.S.T. Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region &#8211; Global Forecast to 2022-2033&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The cancer immunotherapy market size is estimated to be USD 110,125.4 million in 2022 and is expected to witness a CAGR of 7.51% during the forecast period 2023-2033. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53431","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Worldwide Cancer Immunotherapy Industry to 2033 - Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Worldwide Cancer Immunotherapy Industry to 2033 - Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region &#8211; Global Forecast to 2022-2033&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The cancer immunotherapy market size is estimated to be USD 110,125.4 million in 2022 and is expected to witness a CAGR of 7.51% during the forecast period 2023-2033. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T18:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Worldwide Cancer Immunotherapy Industry to 2033 &#8211; Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2023-01-30T18:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/\"},\"wordCount\":476,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005607\\\/en\\\/1699652\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/\",\"name\":\"Worldwide Cancer Immunotherapy Industry to 2033 - Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005607\\\/en\\\/1699652\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-30T18:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005607\\\/en\\\/1699652\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005607\\\/en\\\/1699652\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Worldwide Cancer Immunotherapy Industry to 2033 &#8211; Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Worldwide Cancer Immunotherapy Industry to 2033 - Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Worldwide Cancer Immunotherapy Industry to 2033 - Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region &#8211; Global Forecast to 2022-2033&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The cancer immunotherapy market size is estimated to be USD 110,125.4 million in 2022 and is expected to witness a CAGR of 7.51% during the forecast period 2023-2033. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-30T18:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Worldwide Cancer Immunotherapy Industry to 2033 &#8211; Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others &#8211; ResearchAndMarkets.com","datePublished":"2023-01-30T18:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/"},"wordCount":476,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/","name":"Worldwide Cancer Immunotherapy Industry to 2033 - Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/21\/logo.jpg","datePublished":"2023-01-30T18:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230130005607\/en\/1699652\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/worldwide-cancer-immunotherapy-industry-to-2033-featuring-novartis-pfizer-astrazeneca-and-genentech-among-others-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Worldwide Cancer Immunotherapy Industry to 2033 &#8211; Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53431"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53431\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}